ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2017
Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026Article
- Stimuli-Responsive Carriers for Delivery of Anticancer Bioactive Agents.Materials (Basel, Switzerland) · 2026Review
- Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration.Frontiers in pharmacology · 2026Article
- Nanoparticle-based drug delivery systems in urologic oncology: From targeted therapy to precision theranostics.Materials today. Bio · 2025Review
- Review
- Progress on liposome delivery systems in the treatment of bladder cancer.RSC advances · 2025Review
- Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice.International journal of molecular sciences · 2024Article
- Perturbation of Copper Homeostasis Sensitizes Cancer Cells to Elevated Temperature.International journal of molecular sciences · 2023Article
- Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.Pharmaceutics · 2023Review
- Review
- Current applications of nanomaterials in urinary system tumors.Frontiers in bioengineering and biotechnology · 2023Review
- A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.Scientific reports · 2022Article
- Transcriptional activation of ENPP2 by FoxO4 protects cardiomyocytes from doxorubicin‑induced toxicity.Molecular medicine reports · 2021Article
- Review
- DPPGInternational journal of nanomedicine · 2021Article
- Real-time fluorescence imaging for visualization and drug uptake prediction during drug delivery by thermosensitive liposomes.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2019Article
- Intravesical device-assisted therapies for non-muscle-invasive bladder cancer.Nature reviews. Urology · 2018Review
- Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
purposeTo evaluate lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox MATERIAL AND
methodsPorcine in vivo studies were performed with the following groups: (i) intravenous (IV) LTLD with hyperthermia (LTLD + HT); (ii) IV doxorubicin (DOX) with hyperthermia (IV DOX + HT) and (iii) IV LTLD without hyperthermia (LTLD - HT). Drug formulations were delivered via 30 min IV infusion coinciding with 1-h bladder irrigation (45 °C water for HT groups, 37 °C for non-HT group), followed by immediate bladder resection. DOX concentrations were measured in consecutive sections parallel to the bladder lumen by liquid chromatography following drug extraction. Computer models were developed to simulate tissue heating and drug release from LTLD.
resultsComparing mean DOX concentrations at increasing depths from the lumen to outer surface of the bladder wall, the ranges for LTLD + HT, IV DOX + HT and LTLD - HT, respectively, were 20.32-3.52 μg/g, 2.34-0.61 μg/g and 2.18-0.51 μg/g. The average DOX concentrations in the urothelium/lamina and muscularis, respectively, were 9.7 ± 0.67 and 4.09 ± 0.81 μg/g for IV LTLD + HT, 1.2 ± 0.39 and 0.86 ± 0.24 μg/g for IV DOX + HT, and 1.15 ± 0.38 and 0.62 ± 0.15 μg/g for LTLD - HT. Computational model results were similar to measured DOX levels and suggest adequate temperatures were reached within the bladder wall for drug release from LTLD.
conclusionsDoxorubicin accumulation and distribution within the bladder wall was achieved at concentrations higher than with free IV doxorubicin by mild bladder hyperthermia combined with systemic delivery of LTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.